HGEN News and Press, Humanigen Inc. From 09/09/21

Humanigen (NASDAQ: HGEN) stock is sinking after the clinical-stage biopharmaceutical company shared devastating news. The FDA has declined Humanigen's request for emergency use authorization of lenzilumab, sending the biotech stock 52.1% lower as of 11:38 a.m. EDT on Thursday. ...

Gainers: ProQR Therapeutics (NASDAQ:PRQR) +22%, Centessa Pharmaceuticals CNTA +22%, Kiromic BioPharma (NASDAQ:KRBP) +19%, Trinity Biotech TRIB +16%, Enveric Biosciences (NASDAQ:ENVB) +14%. Losers: Humanigen HGEN -54%, Invacare IVC -34%,&#...

JP Morgan has cut Humanigen (HGEN -49.0%) to underweight from neutral and is withdrawing its price target after the FDA declined the company's request for an Emergency Use Authorization for lenzilumab for hospitalized COVID-19 patients. Analyst Eric Joseph said he wasn't that surprised with t...

Humanigen (NASDAQ:HGEN) -59% after FDA declined emergency use approval of lenzilumab in COVID-19 Certara (NASDAQ:CERT) -8% after prices equity offering at $31 GameStop (NYSE:GME) -8% on Q2 earnings release DouYu International (NASDAQ:DOYU) -7%. Mechel (NYSE:MTL) ...

FDA has committed to working with Humanigen in the development of lenzilumab and has invited Humanigen to submit additional data as it becomes available NIH’s ACTIV-5/BET-B study is expected to provide further data that may support a new EUA request Humanigen remains co...

As the rapid spread of the COVID-19 Delta variant continues to disrupt several economies, there is growing concern about the virus’ potential long-term physical effects. Given this backdrop, which suggests more therapies will need to be developed, we think it could be wise to investiga...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm’” with its lead drug candidate, lenzilumab, today provided a corporate and regul...

Lenzilumab treatment in Black and African-American patients in the positive LIVE-AIR Phase 3 trial, having a CRP<150 mg/L, resulted in a nearly 9-fold increase in survival without ventilation CDC data shows Black and African-American persons are at an almost 3-fold greater risk...

ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L Study modification may en...

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug ab...